Abstract

Therapeutic Hypothermia (TH) is a standard of care after out-of-hospital cardiac arrest (OHCA). Previous reports failed to prove a significant benefit for survival or neurological outcomes. We examined whether the proper selection of patients would enhance treatment efficacy. We conducted a retrospective cohort study. Data was collected from January 2000 and August 2018. Patients were enrolled after OHCA and classified into two groups, patients treated with TH and patients who were not treated with TH. A total of 92 patients were included in the study. 57 (63%) patients were in the TH Group and 34 (37%) in the Non-TH group. There was no statistical difference in favorable neurological outcomes between the groups. Patients presenting with ventricular fibrillation had a higher 1-year survival rate from TH, while patients with asystole were found to benefit only if they were younger than 65 years (p < .007, p < .02, respectively). Therapeutic Hypothermia patients failed to demonstrate a significant benefit in terms of improved neurological outcomes. Patients treated with TH following ventricular fibrillation experienced the most benefit in terms of 1-year survival, while patients who had suffered from asystole experienced a modest benefit only if they were younger than 65 years of age. Guidelines should address age and primary arrhythmia for proper treatment selection.

Highlights

  • Cardiac Arrest is a sudden cessation of cardiac activity as a result of ventricular fibrillation, asystole, or pulseless electrical activity [1]

  • A total of 92 patients were included in the study. 57 (63%) patients were in the Therapeutic Hypothermia (TH) Group and 34 (37%) in the Non-TH group

  • There was no statistical difference in favorable neurological outcomes between the groups

Read more

Summary

Introduction

Cardiac Arrest is a sudden cessation of cardiac activity as a result of ventricular fibrillation, asystole, or pulseless electrical activity [1]. The most common cause of cardiac arrest is ischemic heart disease [2,3]. The survival rate of cardiac arrest is very low, with a mortality rate of more than 90%. The only intervention therapy that has been studied so far in randomized trials is therapeutic hypothermia [4,5]. Therapeutic hypothermia was presented to the world in the early 1950s following initial reports of clinical benefits, both in terms of survival and neurological outcomes, in several patients who experienced cardiac arrest. Therapeutic Hypothermia (TH) is a standard of care after out-of-hospital cardiac arrest (OHCA). Previous reports failed to prove a significant benefit for survival or neurological outcomes. We examined whether the proper selection of patients would enhance treatment efficacy

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call